Hospital-made CAR-T under one shared regulatory master file
Instead of shipping a patient's cells to a distant factory, hospitals would make CAR-T on site under a shared licence, cutting cost and waiting time.
Academic point-of-care CAR-T already exists: ARI-0001 (Hospital Clinic Barcelona, approved under Spain's hospital exemption at roughly a third of commercial cost), NexCAR19 in India (ImmunoACT, list price around $40,000) and several Chinese and Israeli programmes. The MHRA's 2025 framework for point-of-care and modular manufacturing allows one authorisation to cover multiple hospital sites under a central control site. The proposal is a network of 20-30 hospital GMP suites making a common CD19 (and later BCMA) product from a shared master file, with pooled release testing data and a single outcomes registry.
- Manufacturing cost and time for living and radioactive medicines · Cell therapies take weeks to make for one patient and cost hundreds of thousands of dollars. Isotopes run short.
- Prices and value · New cancer drugs routinely cost over $150,000 a year, often for months of benefit. Systems cannot afford them and patients go bankrupt.